Document Detail


Monitoring of intragraft pressure of rejecting organs: increased tissue pressure can be reduced by hyaluronidase therapy.
MedLine Citation:
PMID:  11152218     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The present study was undertaken in order to: (a) develop a new technique for measurement of interstitial pressure, (b) study the intragraft pressure of rejecting and non-rejecting organs, and (c) study the effect of treatment with the hyaluronan-degrading enzyme hyaluronidase on intragraft pressure. Treatment with hyaluronidase has previously been demonstrated to result not only in reduction of tissue hyaluronan but also in ameliorated interstitial edema, and we suggested that the diminished edema would lead to a reduced interstitial pressure as well. METHODS: At day 5 after syngeneic or allogeneic rat heterotopic heart transplantation, the interstitial pressure of the cardiac grafts was measured using a microtip pressure sensor. Subsequently, the allogeneically grafted animals received a continuous intravenous infusion of either hyaluronidase (total dose: 60,000 U/kg) or vehicle during 2 hr; meanwhile, the interstitial pressure was monitored. RESULTS: The intragraft pressure measurement technique was found to give reproducible results. The interstitial pressure of the rejecting (allogeneic) grafts was considerably higher than that of the non-rejecting (syngeneic), i.e., 12.3+/-1.6 mmHg vs. 1.1+/-0.6 mmHg (P<0.001). Hyaluronidase infusion effectively reduced the interstitial pressure as compared with vehicle treatment. By 20 min, the pressure had been reduced by 28% (P<0.01 compared with vehicle treatment); after 1 hr, by 49% (P<0.001); and after 2 hr, by 68% (P<0.01). CONCLUSIONS: By using modern technology for tissue pressure measurements, we found that the strongly increased interstitial pressure of rejecting organs can be instantly reduced by intravenous administration of the hyaluronan-degrading enzyme hyaluronidase.
Authors:
C Johnsson; G Tufveson; R Hällgren
Related Documents :
11282578 - Winter stem xylem pressure in walnut trees: effects of carbohydrates, cooling and freez...
7681428 - Blood-tissue transport of exogenous albumin and immunoglobulin g in genetically analbum...
2375958 - Effects of vasomotion and venous pressure elevation on capillary-tissue fluid exchange ...
1516068 - Microvascular pressure is the principal driving force for interstitial hypertension in ...
11052438 - Ketamine infusion versus isoflurane for the maintenance of anesthesia in the prebypass ...
18496148 - Red wine polyphenols improve endothelium-dependent dilation in rat cerebral arterioles.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation     Volume:  70     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-01-09     Completed Date:  2001-01-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1575-80     Citation Subset:  IM    
Affiliation:
Department of Transplantation Surgery, University Hospital, Uppsala, Sweden. cecilia.johnsson@kirurgi.uu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Extracellular Space / physiology*
Graft Rejection / physiopathology*
Heart Transplantation / immunology
Histocytochemistry
Hyaluronic Acid / analysis
Hyaluronoglucosaminidase / administration & dosage,  therapeutic use
Injections, Intravenous
Male
Monitoring, Physiologic / methods*
Osmotic Pressure / drug effects
Rats
Rats, Inbred WKY
Chemical
Reg. No./Substance:
9004-61-9/Hyaluronic Acid; EC 3.2.1.35/Hyaluronoglucosaminidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protection of autotransplanted pig kidneys from ischemia-reperfusion injury by polyethylene glycol.
Next Document:  Predictive factors for portal fibrosis in pediatric liver transplant recipients.